A retrospective,double-center study to evaluate the efficacy of switchback from Aflibercept to Ranibizumab in patients with neovascular age-related macular degeneration

Trial Profile

A retrospective,double-center study to evaluate the efficacy of switchback from Aflibercept to Ranibizumab in patients with neovascular age-related macular degeneration

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Ranibizumab (Primary) ; Aflibercept
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top